EP0114758A1 - +/- 2-((3,4-Methylenedioxy)phenethyl)-5-((3-Carboxamido-4-Hydroxy)-alpha-hydroxybenzyl)-Pyrrolidine, pharmazeutische Zusammenstellungen die sie enthalten, Verfahren zur Herstellung und deren Zwischenprodukte - Google Patents

+/- 2-((3,4-Methylenedioxy)phenethyl)-5-((3-Carboxamido-4-Hydroxy)-alpha-hydroxybenzyl)-Pyrrolidine, pharmazeutische Zusammenstellungen die sie enthalten, Verfahren zur Herstellung und deren Zwischenprodukte Download PDF

Info

Publication number
EP0114758A1
EP0114758A1 EP84300387A EP84300387A EP0114758A1 EP 0114758 A1 EP0114758 A1 EP 0114758A1 EP 84300387 A EP84300387 A EP 84300387A EP 84300387 A EP84300387 A EP 84300387A EP 0114758 A1 EP0114758 A1 EP 0114758A1
Authority
EP
European Patent Office
Prior art keywords
carboxamido
methylenedioxy
pyrrolidine
phenethyl
hydroxybenzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP84300387A
Other languages
English (en)
French (fr)
Other versions
EP0114758B1 (de
Inventor
Joseph Martin Muchowski
Jack Ackrell
Jurg Roland Pfister
Robert James Greenhouse
Tsung-Tee Li
Hans Peter Kaiser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/527,716 external-priority patent/US4548949A/en
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of EP0114758A1 publication Critical patent/EP0114758A1/de
Application granted granted Critical
Publication of EP0114758B1 publication Critical patent/EP0114758B1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • This invention concerns +2-[(3,4-methylenedioxy) phenethyl]-5-[(3-carboxamido-4-hydroxy)- ⁇ -hydroxybenzyl] pyrrolidines wnich affect the cardiovascular system and whicn are particularly effective as antihypertensive agents.
  • the invention is directed mainly toward orally active, long lasting cardiovascular regulators of hypertension.
  • the compounds of this invention are also potent bronchodilators.
  • Tne invention is also directed toward pnarmaceutical compositions useful for management of hypertension and toward tne method of use for regulating tne cardiovascular system in mammals.
  • tne exact nature of tne drug various members of the same general class of compounds may be used in the treatment of cardiac disorders sucn as hypertension, cardiac arrhytnmia, and vasal congestion.
  • Tne present invention is directea toward orally active, long acting cardiovascular regulators.
  • the compounds of this invention have a strong antihypertensive activity.
  • the antihypertensive activity of the compounds of this invention is best snown by their effect on the systolic blood pressure.
  • the compounds of this invention decrease significantly the systolic blood presure without at the same time increasing heart rates.
  • the dosage which is needed to decrease systolic blood pressure is very low and tne secondary, often undesirable, side effects are thus avoided.
  • this invention offers tne effective management of hypertension without submitting the treated subject to the undesirable secondary effects which would be unavoidable if large doses are needed.
  • One aspect of this invention relates to compounds of tne formula (I): and their pharmaceutically acceptable acid addition salts, including mixtures of, and individual, stereoisomers, sucn as cis erythro, cis tnreo, trans erytnro and trans tnreo isomers of the compounds.
  • These compounds are potent antihypertensive agents and are therefore useful as cardiovascular system regulators.
  • These compounds of the invention may be prepared in as many as eight possible stereoisomeric forms, and may exist as these stereochemically pure forms; as racemic mixtures containing both members of one enantomeric pair from tne total of four sucn pairs; or, as mixtures of some or all of the diasteromeric forms. The invention is intended to encompass all of these possibilities.
  • Separation of diastereomers can, of course, be carried out by any standard separation technique, such as thin layer or high pressure liquid cnromatography, or even, fractional crystallization.
  • Each racemic diastereomer (or enantiomeric pair) may, if desired, be resolved into its optical antipodes by conventional resolution means; for example by separation (e.g. fractional crystallization) of the diastereomeric salts formed by the reaction of these compounds with optically active acids.
  • optically active acias are tne optically active forms of camphor-10-sulfonic acid, 2-bromo-camphor- -sulfonic acid, camphoric acid, menthoxyacetic acid, tartaric acid, malic acid, diacetyltartaric acid, pyrrolidine-5-carboxylic acid and the like.
  • the separated pure diastereomeric salts may then be cleaved by standard means to afford the respective optical isomers of the compounds of Formula I.
  • Yet another aspect relates to the method of use of the compounds of this invention as cardiovascular regulators and to the pharmaceutical composition useful in regulating cardiovascular disorder, particularly in managing hypertension.
  • a-nydroxybenzyl or "pnenylnydroxymethyl” mean compounds of tne formula
  • Tne ⁇ 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-hydroxy)-a-hydroxybenzyl] pyrrolidines have three cniral centers. Two chiral centers are at the 2- and 5- positions of the pyrrolidine ring at which the side cnains are substituted. The third chiral center is introauced in pyrrolidines where the side chain attached to the 5-position is a-hydroxybenzyl.
  • Embodiments wherein hydrogens at 2- and 5-positions are on tne same side of the plane of the pyrrolidine ring are designated "cis”.
  • Embodiments wnere hydrogens at 2-and 5-position are on opposite sides are "trans.”
  • Erythro/threo terminology is used to designate the relationship between tne configurations of the group attached to the carbon atom bearing the hydroxyl substituent and of the number 5 carbon of the pyrrolidine ring to which it is attached.
  • Erythro indicates those embodiments wherein the hydrogen of carbon atom 5 of the ring and the hydrogen of tne hydroxylatea carbon occupy the same side of tne molecule.
  • More preferred embodiments are compounds of the formula namely, + trans erythro 2-[(3,4-methylenedioxy) pnenethyl]-5-[(3-carboxamido-4-hydroxy)- ⁇ -hydroxybenzyl] pyrrolidine.
  • Most preferred embodiments are compounds of tne formula namely, ⁇ cis erythro 2-[(3,4-methylenedioxy) phenethyl]-5-[(3-carboxamido-4-hydroxy)- ⁇ -hydroxybenzyl] pyrrolidine.
  • Tne compounds of this invention are prepared by the reaction sequence illustrated in Reaction Scheme 1-4.
  • Reaction Scheme 1 illustrates the preparation of + cis erythro 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-hydroxy)-a-hydroxybenzyl] pyrrolidine.
  • Reaction Scneme 2 illustrates the preparation of ⁇ cis threo 2-[(3,4-methylenedioxy) phenethyl]-5-[(3-carboxamido-4-hydroxy)- ⁇ -hydroxybenzyl] pyrrolidine.
  • Reaction Scneme 3 illustrates preparation of + trans erythro 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-hydroxy)-a-hydroxybenzyl]pyrrolidine and Reaction Scheme 4 illustrates preparation of + trans t h reo 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-hydroxy)-a-hydroxybenzyl]pyrrolidine.
  • Step 1 describes the preparation of 2-[(3,4-metnylenedioxy)phenylacetyl]pyrrole (III) from pyrrole (IIb) and [(3,4-methylenedioxy)phenylacetyl] morpholide (IIa).
  • Pyrrole (IIb) is commercialy available from Aldrich.
  • [(3,4-methylenedioxy)phenylacetyl]morpholide (IIa) is prepared by reacting phenylacetic acid with thionyl chloride and with a small amount of dimethylformamide for 10-60 minutes at the temperature of l0-30°C, preferably at room temperature. The resulting mixture is reacted with morpholine dissolved in an organic solvent, preferably in dry dichloromethane, to give [(3,4-methylenedioxy)phenylacetyl]morpholide (IIa).
  • the reaction mixture is stirred for 12-20 hours, alkalized, and purified by methods known in the art to obtain 2-[(3,4-methylenedioxy) p h enylacetyl]pyrrole (III).
  • Step 2 describes the conversion of 2-[(3,4-methylenedioxy)phenylacetyl]pyrrole (III) to 2-[(3,4-methylenedioxy)phenethyl]pyrrole (IV).
  • Step 3 describes the preparation of 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-benzyloxy)benzoyl]pyrrole (V).
  • [(3-carboxamido-4-benzyloxy)benzoyl]morpholide (I) is prepared from (3-carboxamido-4-benzyloxy)benzoic acid by procedure similar to that of Step 1.
  • (3-carboxamido-4-benzyloxy)benzoic acid is prepared from (3-carboxamido-4-hydroxy)benzoic acid which is a known compound of which preparation is described in Brit. Patent 802,841, issued October 15, 1958, in J. Chem. Soc., pp. 4678 (1956), and in Chem. in Industry, pp. 417 (1955)).
  • Benzylation of phenolic hydroxy group begins witn dissolving methyl ester of (3-carboxamido-4-hydroxy) benzoic acid in an organic solvent, preferably in dimethylformamiae, and treating it with metal hydride, preferably with 1 equivalent of sodium hydride, at a temperature of 10-30°C, preferably at room temperature.
  • metal hydride preferably with 1 equivalent of sodium hydride
  • the mixture is stirred until the compounds dissolve, for about 5-6 minutes and benzyl halide, preferably benzyl bromide or chloride is added.
  • the mixure is again stirred at a temperature of 15-50° until reaction is complete, usually for 1-3 hours.
  • the mixture is purified with methods known in the art and the methyl ester (3-carboxamido-4-benzyloxy)benzoic acid is hydrolyzed with aqueous bicarbonate or carbonate in lower alcohol such as methanol or ethanol to obtain (3-carboxamido-4-benzyloxy)benzoic acid which is then submitted to the same procedure as described in Step 1 to obtain [(3-carboxamido-4-benzyloxy)benzoyl]morpholide ( I ).
  • the compound (X) may also be prepared from the (3-nitrile-4-nydroxy)benzoic acid. This compound is known and is described in German Patent 2,224,681, issued on October 10, 1970, and in corresponding Brit. Applic. 16197-7), published on May 21, 1971.
  • (3-nitrile-4-hydroxy)benzoic acid is benzylated using the procedure described above for (3-carboxamido-4-hydroxy)benzoic acid and as such, i.e. (3-nitrile-4-benzyloxy)benzoic acid, (3-nitrile-4-benzyloxy)benzoyl and (3-nitrile-4-benzyloxy)a-hydroxybenzyl is carried through the Steps 3-7, 9-10, 12-14 and 16-17.
  • a nitrile compound is hydrolyzed to the carboxamiao with 10-20% aqueous hydrochloric acid in a polar solvent such as, for example, methanol for about 0,5-5 hours.
  • the nitrile compound can also be hydrolyzed to its corresponding carboxamido compound with 1 equivalent of aqueous sodium hydroxide in a polar solvent.
  • [(3-carboxamido-4-benzyloxy)benzoyl]morpholide is reacted with an acylating agent, preferably phosphorous oxychloride, at a room temperature for 2-4 hours. Then the compound (IV), dissolved in an organic solvent, preferably in 1,2-dichloroethane, is added and the mixture is stirred for 15-21 hours, preferably for 18 hours. The mixture is purified by methods known in the art to give i2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-benzyloxy)benzoyl]pyrrole (V).
  • an acylating agent preferably phosphorous oxychloride
  • Step 4 describes the attachment of the protective group R 2 to the N atom of the pyrrole compound (V).
  • Compound (V) is dissolved in a suspension of an ethereal or dipolar solvent, preferably in dry dimethylformamide, and mixed with sodium hydride. The mixture is heated to 45-60° for 1-3 hours, preferably 2 hours. Suitable N-protecting agent R 2 , such as aroylcnloride, alkanoylchloride, alkylchloroformate, preferably di-t-butylcarbonate, is added and the mixture is stirred at 60-70° for 1-3 hours.
  • Suitable N-protecting agent R 2 such as aroylcnloride, alkanoylchloride, alkylchloroformate, preferably di-t-butylcarbonate
  • Step 5 describes a catalytic reduction of ⁇ 1-t-butoxycarbonyl-2-[(3,4-methylenedioxy)phenetnyl]-5-[(3-carboxamido-4-benzyloxy)benzoyl]pyrrolidine (VII).
  • Pyrrole (VI) is reduced in the presence of the noble metal catalyst, such as rhodium on carbon, rhodium on aluminum, platinum oxide, preferably with platinum on carbon, in the solvent or solvent mixture containing lower alcohol, lower alkyl ester or ethereal solvent.
  • the noble metal catalyst such as rhodium on carbon, rhodium on aluminum, platinum oxide, preferably with platinum on carbon
  • the preferred solvent is ethyl acetate.
  • Reduction is carried on under the mild reaction conditions, at the room temperature and pressure of 1-3 atmospheres, preferably at atmospheric pressure for 15-28 hours, preferably for 22 hours.
  • the reduced compound is purified and crystallized by the methods known in the art to give ⁇ cis 1-t-butoxycarbonyl-2-[(3,4-methylenedioxy) phenethyl]-5-[(3-carboxamido-4-benzyloxy)benzoyl] pyrrolidine (VII).
  • Step 6 describes the removal of the N-protecting R 2 group from the compound (VII).
  • Step 7 describes the reduction of ⁇ cis 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido- 4 -benzyloxy)benzoyl]pyrrolidine trifluoroacetate ( V I II ) to + cis erythro 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-benzyloxy)- ⁇ -hydroxybenzyl] pyrrolidine (IX).
  • Compound (VIII) is reduced to compound (IX) with a metal borohydride, preferably sodium borohydride dissolved in lower alcohol, preferably in ethanol at 0° temperature.
  • a metal borohydride preferably sodium borohydride dissolved in lower alcohol, preferably in ethanol at 0° temperature.
  • the mixture is reacted for 0.5-3 hours and the solvent is removed.
  • the aqueous residue is diluted with base such as sodium carbonate and the product is extracted with an organic solvent, preferably with ethyl acetate.
  • Step 8 describes the conversion of compound (VIII) in which hydroxy group is protected phenolic hydroxyl, for example benzyloxy, to the compound (X) with unprotected hydroxyl.
  • the reduction is conducted in alcohol, preferably methanol, in the presence of 5-50 wt% of the noble metal catalyst, preferably 5-20% palladium on carbon. Reduction proceeds at temperatures of 10-36°, preferably at room temperature, and at atmospheric pressure for 1-100 hours. Purification by methods known in the art and recrystallization from a suitable solvent, preferably acetonitrile, gives compound (X) with unprotected hydroxyl group, namely + cis erythro 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-hydroxy)-a-hydroxybenzyl]pyrrolidine.
  • a suitable solvent preferably acetonitrile
  • Reaction Scheme 2 illustrates preparation of cis tnreo ⁇ 2-[(3,4-methylenedioxy)phenethyl]-5-[( 3 -carboxamido-4-hydroxy)-a-hydroxybenzyl]pyrrolidine.
  • Step 9 describes the reduction of keto compound (VII) to the mixture of a-hydroxybenzyl compounds (XI') and (XI), and subsequent separation of tne obtained mixture into + cis erythro isomer (XI') and cis threo isomer (XI) of N-protected-2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-benzyloxy)-a-hydroxybenzyl]pyrrolidine.
  • Step 9A ⁇ N-protected cis 2-[(3,4-metnylenedioxy) phenethyl]-5-[(3-carboxamido-4-benzyloxy)benzoyl]-pyrrolidine (VII) (see Reaction Scheme 1) is reduced with metal borohydride, preferably witn sodium borohydride, in lower alcohol, preferably ethanol or methanol, at -10 to +20°C, for 0.5-50 hours.
  • metal borohydride preferably witn sodium borohydride
  • the product obtained after purification by methods known in the art is the mixture of both + cis erythro (XI') and + cis tnreo 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-benzyloxy)-a-hydroxybenzyl]pyrolidines (XI).
  • Step 9B Obtained mixture of cis erythro and cis tnreo isomers (XI') and (XI) is separated by thin layer chromatography (TLC), column chromatography, crystallization, or any other common separation technique, preferably by TLC, to obtain + cis erythro 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-benzyloxy)-a-hydroxybenzyl]pyrrolidine (XI') and + cis tnreo 2-[(3,4-methylenedioxy)phenetnyl]-5-[(3-carboxamido-4-benzyloxy)- ⁇ -hydroxybenzyl] pyrrolidine (XI).
  • TLC thin layer chromatography
  • XI' + cis erythro 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-benzyloxy)-a-hydroxybenzy
  • Cis erythro compound (XI I ) is then submitted to Step 6 (Reaction Scheme 1) to remove N-protecting group R 2 .
  • Step 10 describes the removal of the N-protecting group from ⁇ cis threo 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-benzyloxy)-a-nydroxybenzyl]pyrrolidine.
  • a strong protic acid such as hydrochloric acid or hydrobromic acid, preferably trifluoroacetic acid.
  • the mixture is reacted for 1-50 hours at -10 to +20°C temperature.
  • the solvent is evaporated and the residue is purified to obtain ⁇ cis tnreo 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-benzyloxy)-a-hydroxybenzyl]pyrrolidine trifluoroacetate(XII).
  • Step 11 describes the debenzylation of compound (XII) wherein hydroxy group is protected phenolic hydroxyl, for example benzyloxy, to the compound ( XIII ) .
  • the reduction is conducted in alcohol, preferably methanol, in the presence of 5-50 wt% of the noble metal catalyst, preferably 5-20% palladium on carbon. Reduction proceeds at temperatures of 10-36°, preferably at room temperature, and at atmospheric pressure for 1-100 hours. Purification by methods known in the art and recrystallization from a suitable solvent, preferably acetonitrile, gives compound (XIII) with unprotected hydroxyl group.
  • Reaction Scheme 3 illustrates the preparation of ⁇ trans erythro 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-hydroxy)- ⁇ -hydroxybenzyl]pyrrolidine (XVII).
  • Step 12 illustrates the isomerization of ⁇ cis 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-hydroxy)benzoyl]pyrrolidine compound ( V II) to the trans 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-benzyloxy)benzoyl]pyrrolidine compound (XIV).
  • Cis-2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-benzyloxy)benzoyl]pyrrolidine is dissolved in higher alcohol, for example, propanol, butanol, heptanol, pentanol, preferably in t-butanol and potassium in higher alcohol, preferably in t-butanol is added.
  • the mixture is reacted for 1-6 hours, preferably for 2 hours at a temperature of 10-30°, preferably at room temperature.
  • the mixture is quenched with ammonium salt, preferably with saturated ammonium chloride, poured in the water and extracted with organic solvent, preferably witn ethyl acetate.
  • Step 13 describes the removal of the N-protecting group from ⁇ trans 2-[(3,4-methylenedioxy) phenethyl]-5-[(3-carboxamido-4-benzyloxy)benzoyl] pyrrolidine.
  • trans compound (XIV) is added to a strong protic acid, such as hydrochloric acid or hydrobromic acid, preferably to 1 ml of trifluoroacetic acid cooled on ice.
  • a strong protic acid such as hydrochloric acid or hydrobromic acid
  • the mixture is reacted for 1 minute to 5 hours at -10 to +20°C temperature.
  • the solvent is evaporated and the residue is purified to obtain ⁇ trans 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-benzyloxy)benzoyl]pyrrolidine trifluoroacetate (XV).
  • Step 14 describes the reduction of ⁇ trans 2-[(3,4-methylenedioxy)phenetnyl]-5-[(3-carboxamido-4-benzyloxy)benzoyl]pyrrolidine compound (XV) to ⁇ trans erythro 2-[(3,4-methylenedioxy) pnenetnyl]-5-[(3-carboxamido-4-benzyloxy)-a-hydroxybenzyl]pyrrolidine (XVI).
  • the organic layer is evaporated and the residue dissolved in lower alcohol, such as methanol, ethanol, propanol, butanol, preferably in methanol, and acidified with a solution of hydrogen chloride in the same solvent as above, i.e., preferably in methanol to afford ⁇ trans erythro 2-[(3,4-methylenedioxy) p h enethyll-5-[(3-carboxamido-4-benzyloxy)- ⁇ -hydroxybenzyl]pyrrolidine compound ( X V I ).
  • lower alcohol such as methanol, ethanol, propanol, butanol, preferably in methanol
  • Step 15 describes the debenzylation of compound ( XVI ) with protected phenolic hydroxyl, for example benzyloxy, to the compound (XVII) where hydroxyl is unprotected.
  • the reduction is conducted in alcohol, preferably methanol, in tne presence of 5-50 wt% of the noble metal catalyst, preferably 5-20% palladium on carbon, in a nydrogen atmosphere. Reduction proceeds at temperatures of 10-36°, preferably at room temperature, and at atmospheric pressure for 1-100 hours. Purification by methods known in the art and recrystallization from a suitable solvent, preferably acetonitrile, gives compound (XVI I ) with unprotected phenolic hydroxyl group, namely, ⁇ trans erythro 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-hydroxy)-a-hydroxybenzyl]pyrrolidine compound (XVI).
  • Step 16 describes the reduction of N -protected ⁇ trans 2-[(3,4-methylenedioxy)phenethyl]- 5 -[(3-carboxamido-4-benzyloxy)benzoyl]pyrrolidine compound ( X IV) into the N-protected + trans erythro 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-benzyloxy)-a-hydroxybenzyl]pyrrolidine (XVIII) and + trans threo 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-benzyloxy)-a-hydroxybenzyl]-pyrrolidine (XIX).
  • Step 16A Tne reaction begins with the reduction of compound (XIV) with metal borohydride, preferably with sodium borohydride, in lower alcohol, preferably ethanol or methanol, at -10 to +20°C for 0.5-50 hours.
  • metal borohydride preferably with sodium borohydride
  • lower alcohol preferably ethanol or methanol
  • the mixture obtained after purification by methods known in the art consist of both ⁇ trans erythro and ⁇ trans tnreo 2-[(3,4-metnylenedioxy)phenethyl]-5-[(3-carboxamido-4-benzyloxy)-a-hydroxybenzyl]pyrrolidine compounds (XVIII) and (XIX).
  • Step 16B The mixture obtained in Step 16A is separated by TLC, column chromatography, crystallization or any other common separation technique, preferably by T LC, to obtain ⁇ trans erythro 2-[(3,4-methylenedioxy)-phenethyl]-5-[(3-carboxamido-4-benzyloxy)-a-hydroxybenzyl]pyrrolidine (XVIII) and + trans threo 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-benzyloxy)-a-nydroxybenzyl]pyrrolidine (XIX).
  • Step 17 describes the removal of the N-protecting group from the + trans threo 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-benzyloxy)- ⁇ -hydroxybenzyl]pyrrolidine compound ( X I X ).
  • Step 18 describes the debenzylation of compound (XX) with protected pnenolic hydroxyl, for example benzyloxy, to the compound (XXI).
  • the reduction is conducted in alcohol, preferably methanol, in the presence of 5-50 wt% of the noble metal catalyst, preferably 5-20% palladium on carbon. Reduction proceeds at temperatures of 10-36°, preferably at room temperature, and at atmospneric pressure for 1-100 hours. Purification by methods known in the art and recrystallization from a suitable solvent, preferably acetonitrile, gives compound (XXI) with unprotected pnenolic hydroxyl group, namely + trans threo 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-hydroxy)-a-hydroxybenzyl]pyrrolidine.
  • a suitable solvent preferably acetonitrile
  • Isolation, separation, and purification of the desired final compounds and their intermediates from the reaction mixture can be effected by any suitable separation or purification procedure, such as, for example, extraction, filtration, evaporation, distillation, crystallization, thin-layer chromatography, column chromatography, high pressure liquid chromatography, and the like, or by a combination of these procedures. If not otherwise described above, illustrations of suitable isolation, separation and purification procedures can be had by reference to the Examples herein below. However, other isolation, separation and isolation procedures could, of course, also be used.
  • the invention provides a process for preparing a compound of formula (I): or a-pharmaceutically acceptable salt thereof, which process comprises de-protecting a compound of formula (A): wnerein Q is a protecting group; or converting a free base of formula (I) to a salt; or converting one salt of formula (I) to another salt of formula (I); or converting a salt of formula (I) to a free base of formula (I).
  • Suitable protecting groups Q are as hereinbefore described. They may be removed in any convenient manner, such as reduction, hydrolysis and the like, preferably under mild conditions, for example at temperatures between 10-35°C, preferably ambient, and at pressures of 1-5 atmospheres, preferably at atmospheric pressure.
  • Wnen Q is benzyl, then a preferred procedure is as described hereinbefore in the Reaction Schemes.
  • the compounds of the invention are active antihypertensives. When administered orally or subcutaneously, they relieve hypertension in spontaneously hypertensive rats (SHR) but, at the same time they do not affect rate and force of tne heart beat. Accordingly, they are potentially useful as drugs for management of hypertension. They are also active as bronchodilators.
  • Administration of the active compounds and salts described herein can be via any of the accepted modes.of administration for cardiovascular system regulating agents. These metnods include oral or parenteral routes. Parenteral routes include intravenous, subcutaneous, intradermal, or intramuscular administration.
  • Oral mode of administration is referred for daily administration which is necessary in management of hypertension.
  • Parenteral route of administration is the administration of drugs to a patient by injection under or through one or more layers of the skin or mucous membrane. Parenteral administration would preferably be reserved for crisis situations, wherein tne subject is unable to swallow or administer the medication to himself.
  • the amount of active ingredient.administered will, of course, be dependent on the subject being treated, on the severity of the affliction, on the manner of administration and on the judgment of the prescribing physician. However, an effective dosage is in the range of 0.001-50 mg/kg/day, preferably 0.01-1 mg/kg/day. For an average 70 kg human, this would amount to .07-3.500 mg per day, preferably 0.7-70 mg/day.
  • a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium, carbonate, and the like.
  • excipients such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium, carbonate, and the like.
  • Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and tne like.
  • Such compositions may contain 0.1%-95% active ingredient, preferably 1%-70%.
  • Vehicle for parenteral administration, such as, for example, intravenous injections, the compound is dissolved in a vehicle.
  • Vehicle may be, for example, aqueous vehicle, such as sodium chloride injection, Ringer's injection, dextrose injection and others, water miscible vehicle, such as ethyl alcohol, polyethylene glycol of the liquid series or propylene glycol, or nonaqueous vehicles such a corn oil, peanut oil or sesame oil.
  • Vehicle will be buffered to the proper pH in order to stabilize a solution against chemical degradation and formed in such a way as to control isotonicity of injection.
  • Other substances may also be added as antimicrobial or antioxidant agents.
  • administration of the active compounds and salts described herein can be via any of the accepted modes for bronchodilation, i.e., any mode described above can be used and compounds may also be administered in aerosol form.
  • the pharmaceutical compositions may be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage forms suitable for single administration of precise dosages.
  • the pharmaceutical compositions will include a conventional pharmaceutical carrier or excipient, and a compound of this invention or the pharmaceutically acceptable salt as an active ingredient thereof. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
  • composition or formulation to be administered will, in any event, contain a quantity of the active ingredient(s) in an amount effective to alleviate the symptoms of the subject being treated.
  • conventional non-toxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.
  • the active ingredient as defined above may also be formulated as suppositories, using as the carrier for example polyalkylene glycols, such as propylene glycol.
  • Liquid pharmaceutically administerable compositions can be prepared by dissolving or dispersing, or otherwise preparing an active ingredient (as defined above), and mixing it optionally with a pharmaceutical adjuvant in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension.
  • a carrier such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension.
  • the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.
  • nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.
  • This example illustrates tne preparation of [(3-carboxamido-4-benzyloxy)benzoyl]morpholide.
  • This compound can be prepared from the corresponding [(3-carboxamido-4-hydroxy)benzoic acid by protecting the phenolic nydroxy group.
  • Methyl ester (3-carboxamido-4-hydroxy)benzoic acid was prepared according to the procedure described in J. Chem. Soc., pp. 4678 (1956). The procedure is also described in Brit. Pat. 802,841.
  • Methyl ester [(3-carboxamido-4-benzyloxy)benzoic acid is hydrolyzed to benzoic acid with bicarbonate in methanol for about 12 hours to give (3-carboxamido-4-benzyloxy)benzoic acid.
  • Tne product is suspended in ethanol and filtered, air dried, and recrystallized from methanol/acetone to yield ⁇ cis erythro 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-hydroxy)-o-nydroxybenzyl]pyrrolidine bisulfate.
  • the active ingredient is ⁇ cis erythro 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-hydroxy)-a-hydroxybenzyl]-pyrrolidine hydrochloride.
  • Tne above ingredients are thoroughly mixed and pressed into single scored tablets.
  • the above ingredients are mixed and introduced into a hard-shell gelatin capsule.
  • the above ingredients are mixed and introduced into a hard-shell gelatin capsule.
  • the above ingredients are mixed and introduced into a hard-shell gelatin capsule.
  • An injectable preparation buffered to a pH of 7 is prepared having the following composition:
  • An oral suspension is prepared having the following composition:
  • Benzyl-5-acetylsalicylamide (51 g), pyrrolidone hydrotribromide (90 g) and pyrrolidone (18 g) was stirred in tetrahydrofuran (1000 ml) and warmed to gentle reflux for 18 hours.
  • the reaction mixture was cooled and further quantities of pyrrolidone hydrotribromide and pyrrolidone were added.
  • the mixture was refluxed for 15 minutes after each addition. Three additions were made. Namely, 9.0 g, 4.5 g and 4.5 g of pyrrolidone h ydrotribromide, and 18 g, 0.8 g, 0.8 g of pyrollidone, respectively.
  • 5-bromoacetylsalicylamide 50 g was added in portions to a solution of sodium azide (12 g) in dimethylformamide (100 ml), and stirred magnetically. After 18 hours at room temperature water (50 ml) was added from a wash bottle and the mixture stirred for 1 hour. The product was collected by filtration, washed with a little ether and dried. Yield 35 g.
  • Example A The crystalline material was collected by filtration and weighed 12.5 g (Sample A). The filtrate was acidified by dropwise addition of 25% solution of hydrogen chloride in methanol, and 0.5 g of 10% palladium on charcoal was added. The mixture was stirred in a hydrogen atmosphere at pressure for 2 hours, then filtered, evaporated and the oily residue stirred with acetonitrile containing a little methanol. The product was finally crystallized from the ethanol to yield 5.0 g of the cis erythro amino alcohol hydrochloride, m.p. 206-207°C.
  • Sample A (2.5 g) was recrystallized from ethyl acetate six times to give material, m.p. 150-151°C (630 mg). This material was stirred with methanol and acidified with methanolic hydrogen chloride and about 50 mg of 5% palladium on carbon. The solution was stirred in a hydrogen atmosphere for 1 hour, filtered, evaporated and tne residue crystallized from a very small amount of ethanol to yield ⁇ cis tnreo 2[3-carboxamido-4-hydroxyphenyl]hyaroxymethyl-5[3,4-methylenedioxyphenyl]ethyl pyrrolidine hydrochloride, m.p. 188-189°C.
  • Test compounds were randomly assigned to each group. 5 groups received potential antihypertensive agents and 1 control group received vehicle only (water and Tween).
  • Systolic blood pressure i.e., pressure at the appearance of the first pulse
  • the coccygeal arteries of 3 rats were simultaneously occluded by pump-inflated tail cuffs that were automatically inflated to 300 mmHg and then deflated.
  • a pressure curve and tail pulses were simultaneously monitored on an MFE recorder.
  • Four consecutive (at 30 second intervals) traces were recorded for each rat in a given horizontal group at one, two, three and four hours post compound administration. Subsequent horizontal groups were automatically tested in the same manner.
  • the mean systolic blood pressure (SBP) of eacn rat at each observation time was calculated.
  • SBP systolic blood pressure
  • the SBP of the animals in each dose group were compared to the SBP of tne animals in the control group (vehicle only) at each observation time using a one-way analysis of variance test.
  • a compound exhibiting p ⁇ 0.05 at any observation time was considered to exhibit significant antihypertensive activity.
  • Compounds significantly decreasing blood pressure 20 mmHg or more from control values at all four observation times were considered worthy of further examination.
  • heart rates were calculated and tested for significant change from control heart rate values using the two-tailed test. Pressures were read at hours 1, 2, 3 and 4 after dosing on both days 1 and 2.
  • Table 1 summarizes the results obtained by testing two compounds, namely, ⁇ cis erythro 2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-hydroxy)-a-hydroxybenzyl] pyrrolidine (I) and ⁇ cis erythro 2-[(4-methoxy) phenethyl]-5-[(3-carboxamido-4-hydroxy)- ⁇ -hydroxybenzyl] pyrrolidine (II).
  • Table 1 illustrates the superiority of compound I ⁇ cis erytnro 2-[(3,4-methylenedioxy)pnenethyl]-5-[(3-carboxamido-4-hydroxy)-a-hydroxybenzyl]pyrrolidine over compound II ⁇ cis erythro 2-[4-methoxyphenyl]-5-[3-carboxamido-4-hydroxy)- ⁇ -hydroxybenzyl] pyrrolidine.
  • compound I shows its superiority even more clearly.
  • the decrease in systolic blood pressure is significant and similar, in absolute numbers, to that seen with the higher dose. Again, heart rates are lowered.
  • Compound II on the other hand, at dosage 12,5 mg/kg decreases the systolic blood pressure only during the first hour. Then, the decrease is small and insignificant.
  • Table 2 summarizes the results obtained by testing four doses of ⁇ cis erythro 2-[(3,4-methylenedioxy) p h enethyl]-5-[(3-carboxamido-4-nydroxy)-a-hydroxybenzyl]pyrrolidine for period of 1-24 hours after gavage.
  • Doses administered using the procedure described above were 50 mg/kg, 25 mg/kg, 12,5 mg/kg and 6,5 mg/kg.
  • Table 2 illustrates long-lasting antihypertensive effect of compound ⁇ cis erythro 2-[(3,4-methylenedioxy) phenethyl]-5-[(3-carboxamido-4-hydroxy)- ⁇ -hydroxybenzyl] pyrrolidine.
  • the dosage 12,5 mg/kg shows significant lowering of systolic blood pressure up to 4 hours after gavage.
  • the compound has extended systolic blood lowering effect which is significiant for more than 8 hours.
  • the same compound of the invention (as the hydrochloride salt) was administered to five groups of five male mice at different doses per group, intravenously as an aqueous solution, and the mice observed for acute and delayed lethality.
  • the I.V. LD50 of the compound was 118 mg/kg.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
EP84300387A 1983-01-24 1984-01-23 +/- 2-((3,4-Methylenedioxy)phenethyl)-5-((3-Carboxamido-4-Hydroxy)-alpha-hydroxybenzyl)-Pyrrolidine, pharmazeutische Zusammenstellungen die sie enthalten, Verfahren zur Herstellung und deren Zwischenprodukte Expired EP0114758B1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US46020483A 1983-01-24 1983-01-24
US460204 1983-01-24
WOPCT/US83/00098 1983-01-24
US8300098 1983-01-24
US06/527,716 US4548949A (en) 1983-01-24 1983-08-29 +2-[(3,4-Methylenedioxy)phenethyl]-5-[(3-carboxamido-4-hydroxy)-α-hydroxybenzyl]pyrrolidines
US527716 1983-08-29

Publications (2)

Publication Number Publication Date
EP0114758A1 true EP0114758A1 (de) 1984-08-01
EP0114758B1 EP0114758B1 (de) 1986-11-12

Family

ID=27374389

Family Applications (1)

Application Number Title Priority Date Filing Date
EP84300387A Expired EP0114758B1 (de) 1983-01-24 1984-01-23 +/- 2-((3,4-Methylenedioxy)phenethyl)-5-((3-Carboxamido-4-Hydroxy)-alpha-hydroxybenzyl)-Pyrrolidine, pharmazeutische Zusammenstellungen die sie enthalten, Verfahren zur Herstellung und deren Zwischenprodukte

Country Status (7)

Country Link
EP (1) EP0114758B1 (de)
AU (1) AU2370084A (de)
CA (1) CA1227490A (de)
ES (1) ES529087A0 (de)
FI (1) FI840254A (de)
IL (1) IL70752A0 (de)
NO (1) NO840240L (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015824A (en) * 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002672A2 (de) * 1977-12-02 1979-07-11 Byk Gulden Lomberg Chemische Fabrik GmbH Substituierte Pyrrolidine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
EP0010460A1 (de) * 1978-09-22 1980-04-30 Pharmuka Laboratoires Pyrrolidine-2-methanol-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
EP0022408A1 (de) * 1979-07-06 1981-01-14 Roussel-Uclaf Alpha-Phenyl-2-pyrrolidinmethanol-Derivate und ihre Salze, Verfahren zur Herstellung, Verwendung als Arzneimittel und sie enthaltende Zusammensetzungen
EP0050370A1 (de) * 1980-10-20 1982-04-28 Usv Pharmaceutical Corporation Substituierte cyclische Amine
EP0071399A2 (de) * 1981-07-22 1983-02-09 Syntex (U.S.A.) Inc. Substituierte Pyrrolidin-Cardiogefässsystem-Regulatoren und blutdrucksenkende Mittel, ihre Herstellung und Verwendung

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002672A2 (de) * 1977-12-02 1979-07-11 Byk Gulden Lomberg Chemische Fabrik GmbH Substituierte Pyrrolidine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
EP0010460A1 (de) * 1978-09-22 1980-04-30 Pharmuka Laboratoires Pyrrolidine-2-methanol-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
EP0022408A1 (de) * 1979-07-06 1981-01-14 Roussel-Uclaf Alpha-Phenyl-2-pyrrolidinmethanol-Derivate und ihre Salze, Verfahren zur Herstellung, Verwendung als Arzneimittel und sie enthaltende Zusammensetzungen
EP0050370A1 (de) * 1980-10-20 1982-04-28 Usv Pharmaceutical Corporation Substituierte cyclische Amine
EP0071399A2 (de) * 1981-07-22 1983-02-09 Syntex (U.S.A.) Inc. Substituierte Pyrrolidin-Cardiogefässsystem-Regulatoren und blutdrucksenkende Mittel, ihre Herstellung und Verwendung

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015824A (en) * 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
US6153624A (en) * 1998-02-10 2000-11-28 Hoffman-Laroche Inc. Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
AU748335B2 (en) * 1998-02-10 2002-05-30 F. Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives

Also Published As

Publication number Publication date
AU2370084A (en) 1984-07-26
FI840254A0 (fi) 1984-01-23
ES8600760A1 (es) 1985-11-01
ES529087A0 (es) 1985-11-01
EP0114758B1 (de) 1986-11-12
NO840240L (no) 1984-07-25
IL70752A0 (en) 1984-06-29
FI840254A (fi) 1984-07-25
CA1227490A (en) 1987-09-29

Similar Documents

Publication Publication Date Title
US4727160A (en) Method for making 2-azabicyclo-[3.3.0]-octane-3-carboxylic acids
KR890001550B1 (ko) 벤자제핀 유도체의 제조방법
US4824963A (en) Process for the preparation of optically-active carbazole derivatives
KR890003424B1 (ko) 비사이클릭 아미노산 유도체의 제조방법
JPS6315256B2 (de)
KR910000864B1 (ko) 신규의 의약품
EP0090362A2 (de) Neue Derivate von Cycloalka(c)pyrrol-carbonsäuren, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung sowie neue Cycloalka(c)pyrrol-carbonsäuren als Zwischenstufen und Verfahren zu deren Herstellung
EP0014997B1 (de) 4-Aryloxy- und 4-Arylthio-3-phenylpiperidin-Derivate, Verfahren zur Herstellung solcher Verbindungen und diese enthaltende pharmazeutische Zusammensetzungen
EP0009800A2 (de) 4-Phenyl-1,3-benzodiazepine, Verfahren zu ihrer Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und diese Verbindungen zur Verwendung als Arzneimittel
EP0050370A1 (de) Substituierte cyclische Amine
US4010202A (en) 5,6-Dihydroxy aminotetralol compounds
EP0114758B1 (de) +/- 2-((3,4-Methylenedioxy)phenethyl)-5-((3-Carboxamido-4-Hydroxy)-alpha-hydroxybenzyl)-Pyrrolidine, pharmazeutische Zusammenstellungen die sie enthalten, Verfahren zur Herstellung und deren Zwischenprodukte
EP0269599B1 (de) Substituierte 1H-Imidazole
US4543361A (en) ±2-[Phenethyl]-5-[(3,4-methylenedioxy)-α-hydroxybenzyl]pyrrolidine antihypertensives and use thereas
US4548949A (en) +2-[(3,4-Methylenedioxy)phenethyl]-5-[(3-carboxamido-4-hydroxy)-α-hydroxybenzyl]pyrrolidines
US4661514A (en) Pharmaceutical and veterinary compositions for the treatment of ischemic cardiac disorders
US4490392A (en) Benzylalcohol derivative and process for preparing
EP0115413A1 (de) +/- 2-(phenethyl)-5-((3,4-Methylenedioxy)-alpha-hydroxybenzyl)-Pyrrolidine, pharmazeutische Zusammenstellungen die sie enthalten, Verfahren zur Herstellung und deren Zwischenprodukte
US5232947A (en) Oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain
EP0116373B1 (de) 2H-(1)Benzoxepino(5,4-b)-1,4-oxazinderivate
EP0092942B1 (de) Peptide Derivate, deren Herstellung und Anwendung
US4239903A (en) 2-Aminotetralin derivatives and process for producing the same
FR2510575A1 (fr) Nouveaux composes bicycliques, leur procede de preparation et composition pharmaceutique les renfermant
FR2615511A1 (fr) Derives de benzazepines a action therapeutique
US4104402A (en) 5,6-Dihydroxy aminotetralol compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19841221

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 23528

Country of ref document: AT

Date of ref document: 19861115

Kind code of ref document: T

ITF It: translation for a ep patent filed
REF Corresponds to:

Ref document number: 3461281

Country of ref document: DE

Date of ref document: 19870102

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19870130

Year of fee payment: 4

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19870131

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19870131

Year of fee payment: 4

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Effective date: 19880123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19880124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19880131

Ref country code: CH

Effective date: 19880131

BERE Be: lapsed

Owner name: SYNTEX (U.S.A.) INC.

Effective date: 19880131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19880801

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19880930

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19881001

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19890123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19890131

GBPC Gb: european patent ceased through non-payment of renewal fee
EUG Se: european patent has lapsed

Ref document number: 84300387.2

Effective date: 19880913